Innate Pharma (IPHA) Equity Ratio (2017 - 2025)

Innate Pharma has reported Equity Ratio for 9 years, with the latest figure at 0.35 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio fell 535.05% year-over-year to 0.35; the trailing twelve-month figure through Dec 2025 stood at 0.35 (down 535.05% YoY), and the FY2025 full-year result was 0.35, down 535.05% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.35, down from 0.06 in the prior quarter.
• The five-year high for Equity Ratio was 0.5 in Q2 2021, with the low at 0.35 in Q4 2025.
• Historically, Equity Ratio has averaged 0.21 across 5 years, with a median of 0.28 in 2022.
• Annual changes were most pronounced in 2023 — Equity Ratio gained 13.72% — and 2025, when it slumped 535.05%.
• Innate Pharma's Equity Ratio stood at 0.4 in 2021, then slumped by 35.14% to 0.26 in 2022, then rose by 13.72% to 0.3 in 2023, then sank by 73.15% to 0.08 in 2024, then tumbled by 535.05% to 0.35 in 2025.
• The last three Equity Ratio figures came in at 0.35 (Q4 2025), 0.06 (Q2 2025), and 0.08 (Q4 2024), per Business Quant data.